ARVN - Arvinas Inc.

-

$undefined

N/A

(N/A)

Arvinas Inc. NASDAQ:ARVN Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.

Location: | Website: arvinas.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

661.2M

Cash

1.229B

Avg Qtr Burn

-53.78M

Short % of Float

16.32%

Insider Ownership

7.22%

Institutional Own.

-

Qtr Updated

06/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Data readout

Vepdegestrant (ARV-471)(oral ER-targeting PROTAC® protein degrader) Details
Breast cancer, Cancer, Solid tumor/s

Big Mover™

Susp. Mover™

Phase 3

Data readout

Vepdegestrant (ARV-471) Details
Cancer, Breast cancer, Solid tumor/s

Phase 2

Data readout

Phase 1/2

Data readout

ARV-766 +/- abiraterone Details
Solid tumor/s, Castration-resistant prostate cancer, Prostate cancer, Cancer

Phase 1/2

Update

Bavdegalutamide (ARV-110) (PROTAC protein degrader) +/- abiraterone Details
Prostate cancer, Cancer, Castration-resistant prostate cancer, Solid tumor/s

Phase 1/2

Update

Vepdegestrant (ARV-471)+CDK4 inhibitor Details
Cancer, Solid tumor/s, Breast cancer

Phase 1/2

Update

ARV-393 [PROTAC BCL6 degrader] Details
Cancer, B-cell lymphoma, Blood cancer

Phase 1

Data readout

Vepdegestrant (ARV-471) Details
Cancer, Breast cancer, Solid tumor/s

Phase 1

Data readout

Phase 1

Data readout